跳至主要内容
临床试验/NCT02512757
NCT02512757已完成不适用

The AminoIndex™ Study - A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ Technology

Innovis LLC3 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2015年8月13日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
150
试验地点
3
主要终点
The diagnostic performance of AminoIndex™ to discriminate lung cancer patients from high-risk subjects.

研究概览

简要总结

This is a prospective, multi-center study to evaluate the diagnostic performance characteristics of the AminoIndex™ technology among patients at high risk for developing lung cancer as compared with standard lung cancer screening and diagnostic procedures including low-dose CT, high-dose CT, biopsy and histopathology.

详细描述

This is a prospective, multi-center study to evaluate the diagnostic performance characteristics of the AminoIndex™ technology among patients at high risk for developing lung cancer as compared with standard lung cancer screening and diagnostic procedures including low-dose CT, high-dose CT, biopsy and histopathology.

The study will enroll patients into one of three arms:

  1. patients with lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and diagnosed with primary lung cancer who have not yet initiated treatment of any kind for their lung cancer;
  2. patients with lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and determined to not be cancerous OR that have demonstrated no nodule growth for > 2 years by repeat CT imaging; and
  3. patients at high-risk for lung cancer (per NLST guidelines) with no evidence or history of lung cancer (negative LDCT/CT/X-ray).

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 79 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

The diagnostic performance of AminoIndex™ to discriminate lung cancer patients from high-risk subjects.

时间窗: 6 months

To evaluate the diagnostic performance characteristics of the AminoIndex™ technology among patients at high risk for developing lung cancer as compared with standard lung cancer screening and diagnostic procedures including low-dose CT, high-dose CT, biopsy and histopathology.

次要结局

  • The capability of AminoIndex™ to distinguish malignant lung cancer from benign lung nodules.(6 months)
  • Gathering residual patient samples that will be used for discovery research.(6 months)

研究者

发起方
Innovis LLC
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验